Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10/11/16 Pr:NYMX Wins Big on Late-Stage Trial.
Go NYMX
Agree because NYMX is a great stock to buy and hold.
Go NYMX
The shorts will go bankrupt if they don't buy NYMX shares TO COVER their BIG short positions.
Go NYMX
Smart traders DON'T use that kind of video chart anymore because it's worthless and because it's obsolete at least six(6) decades ago.
Go NYMX
* * $NYMX Video Chart 10-11-16 * *
Link to Video - click here to watch the technical chart video
getting very close to NDA filing. Expecting a continued price increase and analysts upgrades on the additional new positive news, all IMO
Link:10/11/16 good news.
http://ih.advfn.com/p.php?pid=nmona&article=72639602
$$$$$$$$ Go NYMX
10/11/16 Pr:NYMX Wins Big on Late-Stage Trial.
Go NYMX
NYMX is a Strong BUY.
NYMX has a consensus analyst price target of $10.25
$$$$$Go NYMX
Link: NYMX price target of $10.25
https://finance.yahoo.com/news/nymox-wins-big-stage-trial-160553965.html
Nymox Wins Big on Late-Stage Trial
NYMX is a great stock. Loaded the low $3.00's again recently and love to sell during the $4.00 to $6.00 runs. I agree main shares are still holding for bigger $$$. I play with the rest here.
should get back in the 5's over the next week. pretty amazing results. and tons of trial data. all imo
NYMX awesome news and run to $4.73 today!
getting close now. Very solid support base formed in these low 3's. I think I will add more here and wait for the excitement to start.
File for Approval this quarter or next:
“Nymox has completed and fully financed the execution of seven Phase 3 U.S. BPH (prostate enlargement) clinical protocols, including 2 prospective randomized multicenter single injection double blind clinical trials; 2 U.S. repeat injection clinical trials; and 3 U.S. blinded long-term clinical trial extension studies. In addition, a number of Phase 3 safety and clinical pharmacology studies and analyses have been completed. The Company expects to file for approvals in the next 1-2 quarters. The Company also expects to report further analyses and results when available in the near future. The Company will publish the findings of the fexapotide clinical trials in peer review medical journals as well as in presentations at medical and urological meetings.
“These prospective study results in blinded placebo crossover patients clearly demonstrate that fexapotide reduces the long-term need for surgery by 82-95% compared to approved conventional BPH treatments”, said Dr. Paul Averback MD, CEO of Nymox. “Fexapotide shows significant efficacy against prostate cancer as a therapeutic, and in addition has been shown to reduce the risk of prostate cancer when fexapotide is used to treat BPH. This is in stark contrast to some conventional BPH treatments in routine clinical use today which on the other hand increase prostate cancer risk, and which have many other well known undesirable side effects,” said Dr. Averback.”
http://ih.advfn.com/p.php?pid=nmona&article=72282314
Great Article Today on NYMX:
http://streetregister.com/2016/09/29/nymox-pharmaceutical-corporation-nasdaqnymx-ignore-the-shorts-2/
Waiting for a buy indicator. Should have a nice jump soon
We need more good news on the prostate cancer study. That will drive the stock price to who knows where. This drug could be a life changer for millions of men and put the urologists and their minions out of business. Release the data and show the world this drug should be on the market NOW.
Why is this stock price so low?
http://ih.advfn.com/videos/educational/nx-1207-a-novel-drug-designed-to-reduce-prostate-enlargement-and-improve-ur_NoRQw9b72WM
I have always said that. I know 4 men in my life as friends and family who have been affected by this and 1 that died from prostate cancer after a long battle. This could have made a difference in each one so they would not have needed surgery if caught early enough.
If this drug works and gets approved it would be a life changer for the male population around the world. BPH and/or prostate cancer affects most men after a certain age and the current treatments suc
I agree a partnership would help a lot.
Yes, that's why I think we need a partnership with BP. This would provide credence to the stock and drug. In turn institutional funds would move in and buy into what the company is "selling." This in turn would provide stability to the stock.
See how the horse must move before the cart?
Because of stupid day traders that move in on the huge runs. They always mess up everything because they buy and if they do not make money in a minute they sell the this low floater drops easy just like we run easy when we get buys on the ask. It is frustrating though.
Of course, with good news we should fly. The question however, is why can't the stock maintain its gains? It seems pop and drop is the MO.
Me too back over $4.00 then $5.00. I think we will get news to do it soon.
looks like low volume slight uptrend taking place. Would like to see NYMX get back over 4 and stay over for good.
I hold a pretty big long position here but will start buying heavy everytime it gets close to 3. It always runs back up. Right now I have to wait on the DRRX FDA decision about 9 days away and then I'll put that money here. all imo, glta longs.
Looks like NYMX found a bottom after all the massive groups loaded the other day. Day traders and flippers always mess up a great run by panic selling on red.
Refer to the insider buys chart even just going back 1 year. The NYMX insider buys are insane. That is likely what sparked todays huge run.
no news and out of the blue pop? don't tell me this will be another EVOK like 2 months ago. OFFERING!
* * $NYMX Video Chart 09-13-16 * *
Link to Video - click here to watch the technical chart video
They always protect themselves with options both down and up follow the volume!
Might be just an extraboost when needet ;) Lets See....
Shorts are always all over NYMX. They will get fried unexpectedly again. Look at the charts. The red and decline has been on tiny daily volume. IMO we will be back over $4.00 and $5.00 soon.
But i am more of a daytrader ,Looking at Volume Spikes... And specialy at Pharma companys... I am Doing more then well with my strategy... But Thats me.. I am 10years now in stockmarket And it took me a while to find my Way,But now it is close to be at it Perfektion for me ;)
But i am also Long in some Stocks wich i See Long for me... AAPL Since close to 10 Years,Facebook Since 40's....
If everyone just came here to day trade forget it. Do some real DD. Go into the charts on insider buys all year long. Go into the charts on the big news in late Aug. This is a good stock to own into much bigger news ahead IMO. The spike today was likely caused by automatic insider buying that lead to short covering.
For me it Looks like we See another Volume Spike and rise in pps soon
Just bought more on this dip.... Lest See ;)
Look at the news in late Aug. we ran to about $6.00. Insider buys have been insane all year. There must be more big news coming IMO. The entire float traded over $5.00 a share on the big news. It has been dropping on tiny volume since then.
Little Late to tha Party,But bought in 3,89...
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
Date : 08/29/2016 @ 10:30AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. This is in stark contrast to some conventional BPH treatments in routine clinical use today which on the other hand increase prostate cancer risk, and which have many other well-known undesirable side effects such as retrograde ejaculation which is when men lose the ability to have normal orgasms.
The same clinical program conducted at the same highly regarded treatment centers under rigorous trial scrutiny and performed strictly at arms-length by top teams of clinical investigators across the country, has now also shown that the long-term blinded placebo crossover group study has resulted in an 82-95% reduction in the number of these patients who required surgery after they received crossover fexapotide in the trial, as compared to patients who did not receive fexapotide but instead received crossover conventional approved BPH treatments (p<.0001). The aim of the crossover study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received placebo, remained blinded as to their placebo treatment, and who subsequently required additional medical and/or surgical treatment. In this study long-term outcomes were determined in 391 patients who were given double blind placebo injections, which were followed by crossover to other treatments at the patients' discretion. The numbers of blinded placebo patients who subsequently received surgical treatment during the next 2-3 years for their BPH symptoms were then prospectively analyzed.
For the long-term cancer incidence analysis, the men in the study received fexapotide or placebo for the treatment of their prostate enlargement (BPH) symptoms. All men were thoroughly evaluated at expert urological testing investigational centers to exclude any prostate cancer prior to qualifying for enrollment in the studies. The participants were enrolled at these over 70 top well-known U.S. urological investigational centers, and were followed for up to 7 years (median of 5 years) after treatment. The study analyzed all cases of prostate cancer that were subsequently diagnosed. The expected rate of new prostate cancer in the U.S. general male population in this age group is in the 5-20% range after 7 years. In the BPH population in published large trials of drugs for the prevention of prostate cancer, the incidence of new prostate cancer cases after 4-7 years has been reported in major studies to be 20-25%. The new data analysis from the Nymox fexapotide study has now shown the statistically significant and very low incidence of 1.3% for prostate cancer in this comparable fexapotide treated BPH population. By comparison, for example in a population of patients with erectile dysfunction treated with PDE5 inhibitor drugs after 4 years the rate of subsequent prostate cancer was 19.5% (and 22.7% in controls) as recently reported in a large U.S. study published in the Journal of Urology (Volume 196; 3, 2016). The quoted study was in a population of middle aged and elderly men without prostate cancer, similar to the Nymox study population.
"These results are astonishingly good. Other drug treatments and controls tested in similar studies have been associated with a prostate cancer incidence 10 times higher than the results reported by Nymox for fexapotide. This is truly good news. The data strongly indicate that in addition to benefit for BPH symptoms, fexapotide will also help to prevent cancer in these patients," said Dr. Ronald Tutrone, one of the Principal Investigators in the Nymox Fexapotide Prostate Cancer and BPH studies. Dr. Tutrone is Chief of the Division of Urology, Greater Baltimore Medical Center; Medical Director of Chesapeake Urology Research Associates and Chairman of the William E. Kalhert Endowment for Urological Research.
“These exciting results from this long-term prospective analysis confirm what I and other researchers have consistently seen in the clinic -- that it is obvious that fexapotide greatly helps patients in terms of symptomatic benefit for their BPH; and with these results, the clinical benefit also results in much less need for surgical intervention over the long-term. I believe these clinical results, combined with previously reported incidence and progression of prostate cancer in this patient population are truly important. Furthermore, the extreme safety of this new drug and the lack of sexual side effects are remarkably helpful for patients,” said Dr. Mo Bidair, Medical Director of San Diego Clinical Trials in San Diego, CA and an Investigator who has participated for many years in the Fexapotide Clinical Trials.
Clinical trial results from Nymox's Phase 2 clinical program for fexapotide previously have been promptly and frequently reported at large national and international urology meetings, after the completion of the studies. There were peer review publications and over 12 well attended presentations to the AUA and EAU as soon as the Phase 2 data was available. The Company now greatly looks forward to publication of the results and to the upcoming presentations of completed Phase 3 data at national and international medical conferences at the appropriate time.
Dr. Paul Averback, CEO of Nymox said, "The new results now add a third dimension to fexapotide utility: clinical prostate cancer prevention. The drug has now demonstrated statistically significant prospective long-term outcome data showing dramatic reduction in the incidence of newly diagnosed prostate cancer after minimal BPH treatment with fexapotide. Nymox announced in Q3 last year that it will seek regulatory approvals for fexapotide for BPH based on the long-term BPH safety and efficacy data announced Q3 last year. We believe that the exciting new prostate cancer prevention results will add significantly to the evidence in fexapotide's favor towards our goal of widespread major benefit for middle-aged and elderly men."
Dr. Averback added, "These prospective study results in blinded placebo crossover patients clearly demonstrate that fexapotide reduces the long-term need for surgery by up to 82-95% compared to approved conventional BPH treatments. We are extremely grateful to the thousands of people who have been part of these clinical trials. The Company also thankfully acknowledges our shareholders for their long-term commitment that supports these studies."
Nymox has completed and fully financed the execution of seven Phase 3 U.S. BPH (prostate enlargement) clinical protocols, including 2 prospective randomized multicenter single injection double blind clinical trials; 2 U.S. repeat injection clinical trials; and 3 U.S. blinded long-term clinical trial extension studies. In addition, a number of Phase 3 safety and clinical pharmacology studies and analyses have been completed. The Company expects to file for approvals in the next 1-2 quarters. The Company also expects to report further analyses and results when available in the near future.
Fexapotide is a safe and painless single injection treatment given in the urologist's office. The drug is in Phase 3 for BPH and Phase 2 for prostate cancer. It has been tested in over 1700 drug and placebo treatment administrations in the U.S. As a treatment for low grade localized BPH, fexapotide shows long-term efficacy without the safety risk and side effect concerns or added cancer risk associated with currently approved BPH treatments. As a treatment for prostate cancer fexapotide was found to lead to highly statistically significant reduction in disease progression in a large 147 patient multi-year Phase 2 study of U.S. men with low grade cancer.
For more information please contact info@nymox.com or 800-936-9669.
I hear ya on that at least your in the game making some coin NYMX!!!
Followers
|
42
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1137
|
Created
|
05/14/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |